Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
Drug Targets and Therapeutics is an open-access international journal publishing studies on discovery and evaluation of molecular targets for new drugs and various disease therapy and their clinical applications. The journal seeks to understand the molecular mechanisms involved in all aspects of human diseases, and aims to provide useful information on the discovery, evaluation and clinical application of target molecules for disease therapy.
• Original research articles
• Brief Report
Ensure that the following items are present:
Manuscripts must be in English, typewritten using Times New Roman fonts (12-point size) only, and double-spaced throughout on A-4 size with at least 2.5 cm margin. Original articles should contain the following sections in the orders listed; Cover letter, Title page, Abstract, Introduction, Materials and Methods, results, Discussion, Conflict of interest, Acknowledgements, References, Tables, Figure legends, and Figures. Each section must begin on a new page and all pages should be numbered consecutively.
A cover letter should include:
This must be provided on a separated page and include:
The abstract must be a single paragraph with no more than 250 words, presenting the hypothesis being tested, general methods, results, and conclusions. Four to six keywords should be provided.
Graphical Abstract (optional)
Authors may submit a visual or graphic abstract depicting an essence of the article, that is intended to catch a reader’s attention. The graphic abstract should use color, be clear, and be entirely original. This must be supplied as the high resolution image file.
The introduction must start on a separate page and should provide the statement of the essential background, the hypothesis being tested, and the purpose of the work.
Materials and Methods
All human and animal studies must have been approved by the author’s institutional review board and the name of the review board and the approval number must be stated. This section must contain sufficient details of all new procedures to provide reproducibility and reliability of the experiments. Published procedures should be briefly summarized by mentioning the reference(s) and only described in detail if the procedures have been modified. The name of manufacturer should be specified with city, state (for USA), and country.
Only the experimental data must be described without further discussion or interpretation. Results are typically presented in figures or tables, with no repetition of numerical values of the data in the text.
This section must be provided separately from the Results. A combined “Results and Discussion” section is not allowed. Speculative discussion is allowed only if it is based on the data presented. Conclusions must be included in the discussion section.
Conflict of Interest
All authors must disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the perceived to influence, their work. Potential sources of conflict of interest include employment, consultancies, honoraria, stock ownership, stock options, expert testimony, grants received and pending, patents received and pending, royalties, and in-kind contributions. Manuscripts that do not include a conflict of interest statement will be returned to the authors for amendment before any editorial consideration.
The section should include credits [last name and initial(s)] for technical assistance, research funding information, financial support, and other appropriate recognition. Research funding must include the funder and grant number.
The list of references must only include works that are cited in the text and that have been published or accepted for publication. Reference list entries should be alphabetized by the last names of the first author of each work. Also, the names of all authors should be provided.
Each table must be double-spaced and provided on a separate page. Tables must be numbered consecutively with Arabic numerals in the order cited in the text. Supply a brief title for each, but place explanatory matter in the footnotes (not in the heading). Do not use internal horizontal and vertical lines. Tables should be editable and not embedded images or excel files.
Legends must provide sufficient explanation for the reader to understand the figure independent of the text.
Figures should be numbered consecutively in the order of first citation in the text, and each figure should be provided on a separate page. Figures should be submitted in different file formats, including TIFF, EPS, JPEG, GIF, high-resolution PDF, and power point format. Figures should be high-resolution images. All figures will be published in color for online version and in black and white for printed version. Figures will be appropriately scaled down and embedded in the paper. The font size of the text contained in the figures should be legible when scaled down.
Review is comprehensive analyses of the important or emerging topics relevant to the Journal’s scope. Review may be invited or unsolicited. The review should have the following sections in the orders listed; a title page, abstract (no more than 250 words), main text (Authors should break up their reviews into headed sections), References, Figures/Tables (a minimum of two figures, one of which should illustrate the major findings/pathways discussed).
Minireview is a concise overview of recent advances in the specified subject area.
Brief report is a short and complete report of novel research findings of high importance to the field. Reports of preliminary experiments are unacceptable. Brief report should be especially significant and timely and reach a clear conclusion.
All meta-analyses should have clear objectives regarding drug targets and their clinical application and be based on thorough, systematic and recent review of the literature. Meta-analyses reports should follow the guidelines above for Full Original Research Articles.
Changes to authorship
Authors should consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list must be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (1) the reason for the change in author list and (2) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Review of Manuscripts
All manuscripts are first evaluated for their scientific content and significance by the editors and will be subjected to at least two independent reviewers. However, editors reserve the right to reject a manuscript if they feel that the manuscript is out of the scope or does not meet the minimal acceptance criteria for publication. The same rules will apply to invited manuscripts.
Authors are responsible for the factual accuracy of their papers. One set of proofs will be supplied for the author to check for typesetting accuracy, to be returned to the publisher within 3 days of receipt. No changes to the original manuscript will be allowed at this stage. In addition, the editors reserve the right to make any necessary correction to a paper prior to publication.
Transfer of Copyright
All authors must sign the ‘Transfer of Copyright’ agreement before the article can be published. This transfer agreement enables the Pharmaceutical Society of Korea to protect the copyrighted material for the authors, but does not relinquish the author’s proprietary rights.
Endnote file for references
Kyungae Nam, Hochul Shin, Byunghyun Bae, EunYoung Kim
Hyun-Myung Back, Seo-A Choi, Myeong Gyu Kim
Jin Yong Song, Wang Tae Lee, Oh Seong Kwon, Yeon Jin Lee, Su Hyun Lee, Yubin Lee, Ji-Yun Lee
Diem Thi Ngoc Huynh, Kyung-Sun Heo